Back to top

Analyst Blog

Trius Therapeutics Remains One Of Our Best Ideas

PFE

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

By Jason Napodano, CFA

On May 7, 2013, Trius Therapeutics (NasdaqGM: reported financial results for the first quarter 2013. Total revenues in the quarter were $1.727 million, and consisted of $0.529 million in contract research from the company's government grants and $1.198 million collaborative and licensing fees from Bayer Pharma AG, the company's partner in Asia/Pacific market for tedizolid phosphate. Revenues were in-line with expectations. Net loss in the quarter totaled $17.3 million, or 38 cents per share.

Cash as of March 31, 2013 stood at $83.8 million. Now that the phase 3 program for tedizolid in ABSSSI has been successfully completed, we see significant potential for non-dilutive cash through the forming of a commercialization partnership in the European Union. We believe a transaction can get done later in 2013.

To download a copy of our full report, click this link: TSRX/May7-Napodano.pdf

Trius remains one of our best ideas in the small-cap biotechnology area, offering investors low development and regulatory risk with potential high investment returns over the next twelve to eighteen months. We believe investors should establish a position in the stock at today's price given the attractive long-term value and potential for meaningful upside in the shares on the signing of a European partnership for tedizolid.

We believe the commercial opportunity for Trius' tedizolid is significant, at roughly $750 million worldwide. We see the story as mostly derisked, given the positive and consistent results from the two phase 3 studies, ESTABLISH-1 and ESTABLISH-2, that show tedizolid is non-inferior to Pfizer's (NYSE:(PFE - Analyst Report$1.3 billion drug, Zyvox (linezolid). We believe tedizolid can gain meaningful market share after commercialization based on superior dosing, safety, tolerability, and potentially improved efficacy in a growing number of vancomycin and linezolid-resistant strains.

Trius plans to file the U.S. NDA application during the second half of 2013. We see $12 as fair-value and believe the name is low risk / high reward at this level.

Visit SCR.Zacks.com for additional information on Zacks Small-Cap Research.

Follow Jason on Twitter: @JNapodano
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%